You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫脈通(02192.HK)年度淨利潤3.3億元 同比增長31.2%
格隆匯 03-24 18:44

格隆匯3月24日丨醫脈通(02192.HK)公告,截至2024年12月31日止年度,集團的收入約人民幣558.5百萬元,較去年同期增長35.5%。集團在拓展收入的同時不斷提升盈利能力,集團的淨利潤增加至人民幣330.3百萬元,同比增長31.2%。截至2024年12月31日止年度的淨利潤率爲59.1%,持續保持較高水平。截至2024年12月31日止年度的經調整淨利潤和經調整淨利潤率分別爲人民幣323.6百萬元和57.9%,繼續在行業中保持領先地位。董事會決議建議末期股息每股股份人民幣0.1366元。

截至2024年底,醫脈通平臺註冊醫師用戶突破7百萬,其中執業醫師超過4百萬,佔中國執業醫師總數的88%。憑藉對於中國醫師在學習、科研、臨牀診療等多個高頻場景的賦能,公司平臺的用戶活躍度不斷提升。2024年,醫脈通平臺去重過後的每月平均活躍用戶數提升至2.65百萬人。公司平臺較高的中國醫師用戶覆蓋率和用戶活躍度,爲公司開展面向企業客戶的精準營銷及智能患者管理解決方案提供了堅實的基礎。通過自主研發的AI驅動醫師畫像引擎、臨牀決策支持工具及智能醫學內容分發系統,公司爲藥械企業構建合規高效的學術教育解決方案,實現學術資源精準匹配與營銷效能提升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account